Search
Patexia Research
Case number 1:22-cv-00352

Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC et al > Documents

Date Field Doc. No.Description (Pages)
Oct 26, 2022 101 SO ORDERED, re 100 Consent Judgment and Order of Injunction, ***Civil Case Terminated. Signed by Judge Gregory B. Williams on 10/26/22. (ntl) (Entered: 10/26/2022) (4)
Oct 26, 2022 102 Report to the Commissioner of Patents and Trademarks. (ntl) (Entered: 10/26/2022) (5)
Oct 24, 2022 100 PROPOSED CONSENT JUDGMENT and Order of Injunction by Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals LLC, Handa Pharmaceuticals, Inc.. (Phillips, John) (Entered: 10/24/2022) (4)
May 24, 2022 99 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Novartis's Preliminary List of Claim Terms and Phrases for Construction and Proposed Claim Constructions filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
May 17, 2022 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorney Jane M. Love for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)
May 17, 2022 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorneys Emil N. Nachman and Anne Y. Brody for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs)
May 17, 2022 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorney Aileen C. Huang for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs)
May 17, 2022 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorney Andrew P. Blythe for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs)
May 17, 2022 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorney Christine L Ranney for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)
May 16, 2022 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorney Robert W. Trenchard for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb)
May 16, 2022 N/A Add Attorneys Pro Hac Vice (0)
Docket Text: Pro Hac Vice Attorney Robert W. Trenchard for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk)
May 13, 2022 N/A SO ORDERED (0)
Docket Text: SO ORDERED, re [98] MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Ph.D., Robert W. Trenchard, Andrew P. Blythe, Anne Y. Brody, Christine L. Ranney, Aileen C. Huang, Sung Bin Lee, and Emil N. Nachman filed by Novartis Pharmaceuticals Corporation. ORDERED by Judge Maryellen Noreika on 22-352. (mdb)
May 13, 2022 98 Main Document (2)
Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Ph.D., Robert W. Trenchard, Andrew P. Blythe, Anne Y. Brody, Christine L. Ranney, Aileen C. Huang, Sung Bin Lee, and Emil N. Nachman - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Jane M. Love, Ph.D., Robert W. Trenchard, Andrew P. Blythe, Anne Y. Brody, Christine L. Ranney, Aileen C. Huang, Sung Bin Lee, and Emil N. Nachman)(Joyce, Alexandra)
May 13, 2022 98 Certifications for Jane M. Love, Ph.D., Robert W. Trenchard, Andrew P. Blythe, (8)
May 11, 2022 N/A Create Case Association (0)
Docket Text: Case associated with lead case: Create association to 1:21-cv-00645-MN. (dlw)
May 11, 2022 97 Scheduling Order (16)
Docket Text: SCHEDULING ORDER: C.A. No. 22-352 is hereby consolidated into C.A. No. 21-645 and all future filings shall be made in C.A. No. 21-645 only. Fact Discovery completed by 8/12/2022. Opening Expert Reports due by 11/9/2022. Rebuttal Expert Reports due by 12/16/2022. Reply Expert Reports due by 1/13/2023. Expert Discovery due by 2/14/2023. Claim Construction Opening Brief served by 8/5/2022. Claim Construction Answering Brief served by 8/19/2022. Claim Construction Reply Brief served by 9/2/2022. Claim Construction Surreply Brief served by 9/9/2022. Joint Claim Construction Brief filed by 9/14/2022. A Markman Hearing is set for 10/6/2022 at 02:00 PM in Courtroom 4A before Judge Maryellen Noreika. A Pretrial Conference is set for 4/3/2023 at 11:00 AM in Courtroom 4A before Judge Maryellen Noreika. A Bench Trial is set for 4/10/2023 at 08:30 AM in Courtroom 4A before Judge Maryellen Noreika. The Court is reserving 5 days for trial with the length and scope to be determined at a later date. Signed by Judge Maryellen Noreika on 5/11/2022. (dlw)
May 10, 2022 N/A Oral Order (0)
Docket Text: ORAL ORDER DENYING [24] Motion for Judgment on the Pleadings - Having reviewed Handa's motion for judgment on the pleadings, the Court does not view the claims to be directed to a patent ineligible observation of a natural phenomenon. Rather, the claims appear to be directed to a method of treating multiple sclerosis in certain patients by administration of a specific amount of a specific compound (fingolimod). On the record before the Court, this is not a patent ineligible natural phenomenon. See Vanda Pharm. Inc. v. Ward Pharm. Int'l Ltd., 887 F.3d 1117 (Fed. Cir. 2018). Therefore, IT IS HEREBY ORDERED that Handa's motion for judgment on the pleadings is DENIED. That being said, to the extent that Handa obtains additional evidence to support its contention and chooses to pursue patent ineligibility at trial, it may use its allocated time to do so. ORDERED by Judge Maryellen Noreika on 5/10/2022. (dlw)
May 4, 2022 95 Proposed Order (16)
Docket Text: PROPOSED ORDER // Scheduling Order by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/4/2022 (dlw).
May 3, 2022 94 Statement (2)
Docket Text: Joint STATEMENT Concerning Transferred Case Pursuant to D. Del. L.R. 81.2 by Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals LLC, Handa Pharmaceuticals, Inc. (Phillips, John) Modified on 5/3/2022 (dlw).
Apr 29, 2022 91 Notice of Appearance (1)
Docket Text: NOTICE of Appearance by John C. Phillips, Jr on behalf of Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals LLC, Handa Pharmaceuticals, Inc. (Phillips, John)
Apr 29, 2022 92 Notice of Appearance (1)
Docket Text: NOTICE of Appearance by David A. Bilson on behalf of Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals LLC, Handa Pharmaceuticals, Inc. (Bilson, David)
Apr 29, 2022 93 Notice of Service (2)
Docket Text: NOTICE OF SERVICE of Plaintiff's Third Set of Requests for the Production of Documents and Things to Handa Neuroscience, LLC, Handa Pharmaceuticals, Inc., Handa Pharma, Inc., and Handa Pharmaceuticals, LLC (No. 59) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra)
Apr 26, 2022 N/A Scheduling Conference (0)
Docket Text: Minute Entry for proceedings held before Judge Maryellen Noreika - Scheduling Conference held on 4/26/2022. Discussion on the issues presented in the parties' proposed scheduling order. The parties shall file an amended proposed order within one week. The Court will fill in the remaining dates not provided during the conference. See transcript for more details. (Court Reporter Deanna Warner.) Associated Cases: 1:20-cv-00133-MN, 1:21-cv-00645-MN, 1:22-cv-00352-MN(mdb)
Apr 26, 2022 90 SO ORDERED (3)
Docket Text: SO ORDERED re (65 in 1:21-cv-00645-MN, 89 in 1:22-cv-00352-MN) Stipulation and Order Regarding the Handa Defendants. Signed by Judge Maryellen Noreika on 4/26/2022. (dlw)
Apr 25, 2022 89 Stipulation (3)
Docket Text: STIPULATION and [Proposed] Order Regarding the Handa Defendants by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
Apr 11, 2022 N/A Order Setting Scheduling Conference (0)
Docket Text: ORAL ORDER Setting Telephonic Scheduling Conference: IT IS HEREBY ORDERED that a telephonic Scheduling Conference is set for 4/26/2022 at 04:45 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 4/11/2022. (dlw)
Apr 6, 2022 87 Main Document (4)
Docket Text: Joint Letter to The Honorable Maryellen Noreika from Daniel M. Silver, Esq. regarding Proposed Scheduling Order (with Disputed Provisions). (Attachments: # (1) Ex. 1 - Novartis v. Handa Proposed Scheduling Order, # (2) Ex. 2 - Novartis v. HEC Proposed Scheduling Order)(Silver, Daniel)
Apr 6, 2022 87 Ex. 1 - Novartis v. Handa Proposed Scheduling Order (17)
Apr 6, 2022 87 Ex. 2 - Novartis v. HEC Proposed Scheduling Order (15)
Mar 23, 2022 N/A Case Assigned/Reassigned (0)
Docket Text: Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb)
Mar 22, 2022 84 Notice of Appearance (1)
Docket Text: NOTICE of Appearance by Daniel M. Silver on behalf of Novartis Pharmaceuticals Corporation (Silver, Daniel)
Mar 22, 2022 85 Notice of Appearance (1)
Docket Text: NOTICE of Appearance by Alexandra M. Joyce on behalf of Novartis Pharmaceuticals Corporation (Joyce, Alexandra)
Mar 22, 2022 86 Notice (Other) (2)
Docket Text: NOTICE of Related Cases by Novartis Pharmaceuticals Corporation (Silver, Daniel)
Mar 21, 2022 82 Main Document Public Docket Sheet (10)
Docket Text: Record of case transferred in from District of California Northern; Case Number in Other District: 5:21-cv-03397. Copy of Docket Sheet and original file
Mar 21, 2022 82 *Restricted* (10)
Mar 21, 2022 83 Letter (2)
Docket Text: Local Counsel Letter sent. Notice of Compliance deadline set for 4/20/2022. (mal)
Mar 16, 2022 79 Status Report (4)
Docket Text: JOINT STATUS REPORT by Novartis Pharmaceuticals Corporation. (Love, Jane) (Filed on 3/16/2022) Modified on 3/16/2022 (kmg, COURT STAFF). [Transferred from California Northern on 3/21/2022.]
Mar 16, 2022 80 Stipulation (6)
Docket Text: STIPULATION WITH PROPOSED ORDER Transferring Case to the District of Delaware and Dismissing D.E. [28] and D.E. [73] as Moot filed by Novartis Pharmaceuticals Corporation. (Love, Jane) (Filed on 3/16/2022)[Transferred from California Northern on 3/21/2022.]
Mar 16, 2022 81 Order (6)
Docket Text:ORDER denying as moot [73] Motion to Shorten Time; granting [80] Stipulation; denying as moot [28] Motion to Stay. Signed by Judge Edward J. Davila on March 16, 2022. The Clerk shall TRANSFER this action to the United States District Court for the District of Delaware. (ejdlc2, COURT STAFF) (Filed on 3/16/2022) [Transferred from California Northern on 3/21/2022.]
Mar 11, 2022 78 Order on Motion for Extension of Time (1)
Docket Text:ORDER re Dkt. No. 77. Signed by Judge Edward J. Davila on March 11, 2022. The Court orders the Parties to submit a joint update by March 16, 2022.(ejdlc2, COURT STAFF) (Filed on 3/11/2022) [Transferred from California Northern on 3/21/2022.]
Mar 3, 2022 77 Patent/Trademark Report to Commissioner (30)
Docket Text: JOINT NOTICE OF SUBSEQUENT DEVELOPMENTS by Novartis Pharmaceuticals Corporation (Love, Jane) (Filed on 3/3/2022) Modified on 3/4/2022 (kmg, COURT STAFF). [Transferred from California Northern on 3/21/2022.]
Feb 8, 2022 75 Transcript (45)
Docket Text: Transcript of Proceedings held on 02/01/2022, before Judge Susan Van Keulen. Court Reporter/Transcriber Summer Fisher, telephone number summer_fisher@cand.uscourts.gov. Per General Order No. 59 and Judicial Conference policy, this transcript may be viewed only at the Clerk's Office public terminal or may be purchased through the Court Reporter/Transcriber until the deadline for the Release of Transcript Restriction. After that date it may be obtained through PACER. Any Notice of Intent to Request Redaction, if required, is due no later than 5 business days from date of this filing. (Re [74] Transcript Order ) Redaction Request due 3/1/2022. Redacted Transcript Deadline set for 3/11/2022. Release of Transcript Restriction set for 5/9/2022. (Related documents(s) [74]) (Fisher, Summer) (Filed on 2/8/2022) [Transferred from California Northern on 3/21/2022.]
Feb 8, 2022 76 Answering Brief in Opposition (6)
Docket Text: OPPOSITION/RESPONSE (re [73] MOTION to Shorten Time ) filed byNovartis Pharmaceuticals Corporation. (Love, Jane) (Filed on 2/8/2022) [Transferred from California Northern on 3/21/2022.]
Feb 4, 2022 73 Main Document (7)
Docket Text: MOTION to Shorten Time filed by Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc., Handa Pharmaceuticals, LLC. (Attachments: # (1) Declaration Declaration of Don Mizerk, # (2) Proposed Order)(Mizerk, Donald) (Filed on 2/4/2022) [Transferred from California Northern on 3/21/2022.]
Feb 4, 2022 73 Declaration Declaration of Don Mizerk (13)
Feb 4, 2022 73 Proposed Order (2)
Feb 4, 2022 74 Order (2)
Docket Text: TRANSCRIPT ORDER for proceedings held on February 1, 2022 before Magistrate Judge Susan van Keulen by Novartis Pharmaceuticals Corporation, for Court Reporter Summer Fisher. (Trenchard, Robert) (Filed on 2/4/2022)[Transferred from California Northern on 3/21/2022.]
Feb 3, 2022 72 Protective Order (21)
Docket Text:PROTECTIVE ORDER [60]. Signed by Judge Susan van Keulen on 2/3/2022. (svklc2, COURT STAFF) (Filed on 2/3/2022) [Transferred from California Northern on 3/21/2022.]
Feb 2, 2022 69 Order (2)
Docket Text:Order on Joint Discovery Submissions re Dkts. [59] [60] [61]. Signed by Judge Susan van Keulen on 2/2/2022. (svklc2, COURT STAFF) (Filed on 2/2/2022) [Transferred from California Northern on 3/21/2022.]
Feb 2, 2022 70 Order (2)
Docket Text:Order Directing Parties to Disclose Facts re ESI [59]. Signed by Judge Susan van Keulen on 2/2/2022. (svklc2, COURT STAFF) (Filed on 2/2/2022) [Transferred from California Northern on 3/21/2022.]
Feb 2, 2022 71 Order (6)
Docket Text:Order for Discovery of ESI [59]. Signed by Judge Susan van Keulen on 2/2/2022. (svklc2, COURT STAFF) (Filed on 2/2/2022) [Transferred from California Northern on 3/21/2022.]
Feb 1, 2022 N/A Discovery Hearing (0)
Docket Text:Minute Entry for proceedings held before Magistrate Judge Susan van Keulen: Discovery Hearing held on 2/1/2022 via Zoom.
Order(s) to issue.

Total Time in Court: 10:00-11:07am (1 hour 7 mins).
Court Reporter: Summer Fisher.
Plaintiff Attorney: Jane M. Love, Ph. D. & Robert Trenchard.
Defendant Attorney: Don J. Mizerk.

(This is a text-only entry generated by the court. There is no document associated with this entry.) (jhf, COURT STAFF) (Date Filed: 2/1/2022)[Transferred from California Northern on 3/21/2022.]

Jan 31, 2022 67 Main Document (1)
Docket Text:TENTATIVE RULING REGARDING JOINT DISCOVERY SUBMISSION RE [DKT. [59]]. Signed by Judge Susan van Keulen on 1/31/22. (Attachments: # (1) Court Redline to Proposed Order
59-2
.)

(jhf, COURT STAFF) (Filed on 1/31/2022) Modified on 1/31/2022 (sp, COURT STAFF). [Transferred from California Northern on 3/21/2022.]
Jan 31, 2022 67 Exhibit Court Redline to Proposed Order 59-2 (9)
Jan 19, 2022 N/A Notice (Other) (0)
Docket Text: CLERK'S NOTICE: The parties are hereby notified that the Initial Case Management Conference is rescheduled to 4/7/2022 at 10:00 AM in San Jose, Courtroom 4, 5th Floor before Judge Edward J. Davila. An updated Case Management Statement is due by 3/28/2022. (This is a text-only entry generated by the court. There is no document associated with this entry.) (shy, COURT STAFF) (Filed on 1/19/2022) [Transferred from California Northern on 3/21/2022.]
Jan 19, 2022 N/A Notice (Other) (0)
Docket Text: CLERK'S NOTICE: The parties are hereby notified that the Initial Case Management Conference is rescheduled from 4/7/2022 to 4/14/2022 at 10:00 AM in San Jose, Courtroom 4, 5th Floor before Judge Edward J. Davila. An updated Case Management Statement is due by 4/4/2022. (This is a text-only entry generated by the court. There is no document associated with this entry.) (shy, COURT STAFF) (Filed on 1/19/2022) [Transferred from California Northern on 3/21/2022.]
Jan 18, 2022 64 Statement (30)
Docket Text: SECOND UPDATED JOINT CASE MANAGEMENT STATEMENT filed by Novartis Pharmaceuticals Corporation. (Love, Jane) (Filed on 1/18/2022) Modified on 1/20/2022 (gba, COURT STAFF). [Transferred from California Northern on 3/21/2022.]
Jan 7, 2022 N/A Notice (Other) (0)
Docket Text:CLERKS NOTICE SETTING ZOOM DISCOVERY HEARING.
Discovery Hearing re [59],[60] and [61] set for 2/1/2022 10:00 AM in San Jose, - Videoconference Only before Magistrate Judge Susan van Keulen. This proceeding will be held via a Zoom webinar.

Webinar Access: All counsel, members of the public, and media may access the webinar information at https://www.cand.uscourts.gov/svk

Court Appearances: Advanced notice is required of counsel or parties who wish to be identified by the court as making an appearance or will be participating in the argument at the hearing. A list of names and emails must be sent to the CRD at SVKcrd@cand.uscourts.gov no later than January 31, 2022 at 12:00PM PST.

General Order 58. Persons granted access to court proceedings held by telephone or videoconference are reminded that photographing, recording, and rebroadcasting of court proceedings, including screenshots or other visual copying of a hearing, is absolutely prohibited.

Zoom Guidance and Setup:https://www.cand.uscourts.gov/zoom/.

(This is a text-only entry generated by the court. There is no document associated with this entry.) (jhf, COURT STAFF) (Filed on 1/7/2022) [Transferred from California Northern on 3/21/2022.]
Jan 6, 2022 62 Order (1)
Docket Text:ORDER by Judge Susan van Keulen denying as moot [51] Defendants' Motion to Shorten Time. (svklc2, COURT STAFF) (Filed on 1/6/2022) [Transferred from California Northern on 3/21/2022.]
Dec 23, 2021 61 Main Document (8)
Docket Text: Joint Discovery Letter Brief re Requests for Production and Interrogatories filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C)(Love, Jane) (Filed on 12/23/2021)[Transferred from California Northern on 3/21/2022.]
Dec 23, 2021 61 Exhibit A (33)
Dec 23, 2021 61 Exhibit B (11)
Dec 23, 2021 61 Exhibit C (39)
Dec 22, 2021 59 Main Document (8)
Docket Text: Joint Discovery Letter Brief re ESI ORDER filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Love, Jane) (Filed on 12/22/2021) [Transferred from California Northern on 3/21/2022.]
Dec 22, 2021 59 Exhibit A (2)
Dec 22, 2021 59 Exhibit B (8)
Dec 22, 2021 60 Main Document (8)
Docket Text: Joint Discovery Letter Brief re Protective Order filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A)(Love, Jane) (Filed on 12/22/2021) [Transferred from California Northern on 3/21/2022.]
Dec 22, 2021 60 Exhibit A (22)
Nov 26, 2021 58 Answering Brief in Opposition (7)
Docket Text: OPPOSITION/RESPONSE (re [55] MOTION for Leave to File a Response and Supplemental Materials ) Defendants' Opposition to Novartis' Motion for Leave filed byHanda Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc., Handa Pharmaceuticals, LLC. (Mizerk, Donald) (Filed on 11/26/2021) [Transferred from California Northern on 3/21/2022.]
Nov 23, 2021 57 Statement (5)
Docket Text: Statement Opposing Novartis Pharmaceuticals Corporation's re [52] Notice of Pendency of Other Action Involving Same Patent by Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc., Handa Pharmaceuticals, LLC. (Mizerk, Donald) (Filed on 11/23/2021) Modified on 11/29/2021 (gba, COURT STAFF). [Transferred from California Northern on 3/21/2022.]
Nov 22, 2021 55 Main Document (4)
Docket Text: MOTION for Leave to File a Response and Supplemental Materials filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Proposed Order, # (2) Declaration of R. Trenchard, # (3) Brief, # (4) Exhibit 1, # (5) Exhibit 2, # (6) Exhibit 3, # (7) Exhibit 4, # (8) Exhibit 5, # (9) Exhibit 6)(Love, Jane) (Filed on 11/22/2021) [Transferred from California Northern on 3/21/2022.]
Nov 22, 2021 55 Proposed Order (2)
Nov 22, 2021 55 Declaration of R. Trenchard (3)
Nov 22, 2021 55 Brief (5)
Nov 22, 2021 55 Exhibit 1 (32)
Nov 22, 2021 55 Exhibit 2 (1)
Nov 22, 2021 55 Exhibit 3 (1)
Nov 22, 2021 55 Exhibit 4 (1)
Nov 22, 2021 55 Exhibit 5 (1)
Nov 22, 2021 55 Exhibit 6 (3)
Nov 22, 2021 56 Main Document (3)
Docket Text: Administrative Motion to File Under Seal ( re [55] MOTION for Leave to File a Response and Supplemental Materials ) filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Brief, # (2) Exhibit 1, # (3) Exhibit 2, # (4) Exhibit 3, # (5) Exhibit 4, # (6) Exhibit 5)(Love, Jane) (Filed on 11/22/2021) [Transferred from California Northern on 3/21/2022.]
Nov 22, 2021 56 *Restricted* (3)
Nov 22, 2021 56 *Restricted* (3)
Nov 22, 2021 56 *Restricted* (3)
Nov 22, 2021 56 *Restricted* (3)
Nov 22, 2021 56 *Restricted* (3)
Nov 22, 2021 56 *Restricted* (3)
Nov 12, 2021 53 Answering Brief in Opposition (6)
Docket Text: OPPOSITION/RESPONSE (re [51] MOTION to Shorten Time Defendants' Local Rule 6-3 Motion to Shorten Time ) filed byNovartis Pharmaceuticals Corporation. (Love, Jane) (Filed on 11/12/2021)[Transferred from California Northern on 3/21/2022.]
Nov 12, 2021 54 Main Document (2)
Docket Text: Declaration of ROBERT W. TRENCHARD in Support of [53] Opposition/Response to Motion [51] to Shorten Time filed byNovartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit 1, R. Trenchard Decl, # (2) Exhibit 2, R. Trenchard Decl, # (3) Exhibit 3, R. Trenchard Decl)(Related document(s)[53]) (Love, Jane) (Filed on 11/12/2021) [Transferred from California Northern on 3/21/2022.]
Nov 12, 2021 54 Exhibit 1, R. Trenchard Decl (5)
Nov 12, 2021 54 Exhibit 2, R. Trenchard Decl (16)
Nov 12, 2021 54 Exhibit 3, R. Trenchard Decl (5)
Nov 9, 2021 52 Notice (Other) (3)
Docket Text: NOTICE of Pendency of Other Action Involving Same Patent by Novartis Pharmaceuticals Corporation (Second Notice) (Love, Jane) (Filed on 11/9/2021) [Transferred from California Northern on 3/21/2022.]
Nov 8, 2021 50 Main Document (4)
Docket Text: NOTICE by Handa Neuroscience, LLC re [28] MOTION to Stay in Favor of First-Filed CaseNotice of Supplemental Authority Concerning Novartis' Motion to Stay (Attachments: # (1) Attachment A - Celgene)(Mizerk, Donald) (Filed on 11/8/2021) [Transferred from California Northern on 3/21/2022.]
Nov 8, 2021 50 Attachment A - Celgene (30)
Nov 8, 2021 51 Main Document (5)
Docket Text: MOTION to Shorten Time Defendants' Local Rule 6-3 Motion to Shorten Time filed by Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc., Handa Pharmaceuticals, LLC. (Attachments: # (1) Declaration of Don Mizerk In Support, # (2) Proposed Order)(Mizerk, Donald) (Filed on 11/8/2021) [Transferred from California Northern on 3/21/2022.]
Nov 8, 2021 51 Declaration of Don Mizerk In Support (3)
Nov 8, 2021 51 Proposed Order (1)
Nov 4, 2021 49 Main Document (4)
Docket Text: OPPOSITION/RESPONSE (re [28] MOTION to Stay in Favor of First-Filed Case ) Defendant Handa Neuroscience, LLC's Submission of Supplementary Materials In Support of Handa's Opposition to Novartis' Motion to Stay (D.I. 36) filed byHanda Neuroscience, LLC. (Attachments: # (1) Exhibit A - Correspondence, # (2) Exhibit B - FDA, # (3) Exhibit C - Dist. Del., # (4) Exhibit D - White House)(Mizerk, Donald) (Filed on 11/4/2021)[Transferred from California Northern on 3/21/2022.]
Nov 4, 2021 49 Exhibit A - Correspondence (5)
Nov 4, 2021 49 Exhibit B - FDA (5)
Nov 4, 2021 49 Exhibit C - Dist. Del. (20)
Nov 4, 2021 49 Exhibit D - White House (6)
Oct 29, 2021 N/A Notice (Other) (0)
Docket Text: CLERK'S NOTICE CONTINUING HEARING. Please take NOTICE that the Initial Case Management Conference set for 11/4/2021 is HEREBY CONTINUED to 1/27/2022 10:00 AM in San Jose, Courtroom 4, 5th Floor. Updated Joint Case Management Statement due by 1/18/2022. (This is a text-only entry generated by the court. There is no document associated with this entry.) (amk, COURT STAFF) (Filed on 10/29/2021) [Transferred from California Northern on 3/21/2022.]
Oct 25, 2021 47 Main Document (37)
Docket Text: CASE MANAGEMENT STATEMENT (Updated Joint) filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C)(Blythe, Andrew) (Filed on 10/25/2021)[Transferred from California Northern on 3/21/2022.]
Oct 25, 2021 47 Exhibit A (5)
Oct 25, 2021 47 Exhibit B (20)
Oct 25, 2021 47 Exhibit C (10)
Oct 4, 2021 46 Notice of Appearance (2)
Docket Text: NOTICE of Appearance by Andrew Philip Blythe (for Novartis Pharmaceuticals Corporation) (Blythe, Andrew) (Filed on 10/4/2021) [Transferred from California Northern on 3/21/2022.]
Sep 20, 2021 N/A Notice (Other) (0)
Docket Text: CLERK'S NOTICE CONTINUING HEARING. Please take NOTICE that the Initial Case Management Conference set for 9/30/2021 is HEREBY CONTINUED to 11/4/2021 10:00 AM in San Jose, Courtroom 4, 5th Floor. Joint Case Management Statement due by 10/25/2021. (This is a text-only entry generated by the court. There is no document associated with this entry.) (amkS, COURT STAFF) (Filed on 9/20/2021) [Transferred from California Northern on 3/21/2022.]
Aug 30, 2021 N/A Notice (Other) (0)
Docket Text: (Text Only) CLERKS NOTICE TAKING MOTIONS UNDER SUBMISSION WITHOUT ORAL ARGUMENT. The Motion for Judgment on the Pleadings (Docket Item No. [24]) and Motion to Stay (Docket Item No. [28]) before Judge Edward J. Davila previously noticed for 9/9/2021 at 9:00 AM have been taken under submission without oral argument pursuant to Civ. L.R. 7-1(b). The 9/9/2021 hearing is VACATED NO APPEARANCE NECESSARY. The Court to issue further Order on the submitted motions. This is a text only docket entry, there is no document associated with this notice. (amkS, COURT STAFF) (Filed on 8/30/2021) Modified on 8/30/2021 (amkS, COURT STAFF). [Transferred from California Northern on 3/21/2022.]
Aug 12, 2021 43 Main Document (2)
Docket Text: EXHIBITS re [41] Exhibits, [40] Reply to Opposition/Response filed byNovartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit 1, R. Trenchard Decl)(Related document(s)[41], [40]) (Trenchard, Robert) (Filed on 8/12/2021)[Transferred from California Northern on 3/21/2022.]
Aug 12, 2021 43 Exhibit 1, R. Trenchard Decl (7)
Aug 11, 2021 40 Main Document (11)
Docket Text: REPLY (re [28] MOTION to Stay in Favor of First-Filed Case ) filed byNovartis Pharmaceuticals Corporation. (Attachments: # (1) Declaration of R. Trenchard)(Love, Jane) (Filed on 8/11/2021)[Transferred from California Northern on 3/21/2022.]
Aug 11, 2021 40 Declaration of R. Trenchard (3)
Aug 11, 2021 41 Main Document (3)
Docket Text: EXHIBITS re [40] Reply to Opposition/Response (re [28] MOTION to Stay in Favor of First-Filed Case ) filed byNovartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit 1, R. Trenchard Decl, # (2) Exhibit 2, R. Trenchard Decl, # (3) Exhibit 3, R. Trenchard Decl, # (4) Exhibit 4, R. Trenchard Decl, # (5) Exhibit 5, R. Trenchard Decl, # (6) Exhibit 6, R. Trenchard Decl, # (7) Exhibit 7, R. Trenchard Decl)(Related document(s)[40]) (Love, Jane) (Filed on 8/11/2021)[Transferred from California Northern on 3/21/2022.]
Aug 11, 2021 41 Exhibit 1, R. Trenchard Decl (1)
Aug 11, 2021 41 Exhibit 2, R. Trenchard Decl (4)
Aug 11, 2021 41 Exhibit 3, R. Trenchard Decl (3)
Aug 11, 2021 41 Exhibit 4, R. Trenchard Decl (5)
Aug 11, 2021 41 Exhibit 5, R. Trenchard Decl (5)
Aug 11, 2021 41 Exhibit 6, R. Trenchard Decl (30)
Aug 11, 2021 41 Exhibit 7, R. Trenchard Decl (77)
Aug 11, 2021 42 Main Document (4)
Docket Text: Administrative Motion to File Under Seal Documents in Support of [40] REPLY (re [28] MOTION to Stay in Favor of First-Filed Case ) filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Proposed Order, # (2) Declaration of R. Trenchard, # (3) REPLY (re [28] MOTION to Stay in Favor of First-Filed Case ) - Redacted, # (4) REPLY (re [28] MOTION to Stay in Favor of First-Filed Case ), # (5) Exhibit 6 (Redacted), # (6) Exhibit 6 (Unredacted), # (7) Exhibit 7 (Redacted), # (8) Exhibit 7 (Unredacted), # (9) Certificate/Proof of Service)(Love, Jane) (Filed on 8/11/2021) [Transferred from California Northern on 3/21/2022.]
Aug 11, 2021 42 Proposed Order (3)
Aug 11, 2021 42 Declaration of R. Trenchard (5)
Aug 11, 2021 42 REPLY (re [28] MOTION to Stay in Favor of First-Filed Case ) - Redacted (11)
Aug 11, 2021 42 *Restricted* (11)
Aug 11, 2021 42 Exhibit 6 (Redacted) (30)
Aug 11, 2021 42 *Restricted* (30)
Aug 11, 2021 42 Exhibit 7 (Redacted) (77)
Aug 11, 2021 42 *Restricted* (77)
Aug 11, 2021 42 Certificate/Proof of Service (2)
Aug 3, 2021 39 Reply to Response to Motion (18)
Docket Text: REPLY (re [24] MOTION for Judgment on the Pleadings ) Defendant Handa Neuroscience, LLC's Reply in Support of Motion for Judgment on the Pleadings filed byHanda Neuroscience, LLC. (Mizerk, Donald) (Filed on 8/3/2021)[Transferred from California Northern on 3/21/2022.]
Jul 28, 2021 36 Answering Brief in Opposition (21)
Docket Text: OPPOSITION/RESPONSE (re [28] MOTION to Stay in Favor of First-Filed Case ) filed byHanda Neuroscience, LLC. (Mizerk, Donald) (Filed on 7/28/2021) [Transferred from California Northern on 3/21/2022.]
Jul 28, 2021 37 Main Document (4)
Docket Text: DECLARATION of Don J. Mizerk in Opposition to [36] Opposition/Response to Motion filed byHanda Neuroscience, LLC. (Attachments: # (1) Exhibit A - Elan Pharma 21, # (2) Exhibit B - Elan Pharma Docket, # (3) Exhibit C - Law 360 Article, # (4) Exhibit D - July Email, # (5) Exhibit E - Production Letter, # (6) Exhibit F - Correspondence, # (7) Exhibit G - 11-2-2006 Order, # (8) Exhibit H - Opinion)(Related document(s)[36]) (Mizerk, Donald) (Filed on 7/28/2021)[Transferred from California Northern on 3/21/2022.]
Jul 28, 2021 37 Exhibit A - Elan Pharma 21 (2)
Jul 28, 2021 37 Exhibit B - Elan Pharma Docket (30)
Jul 28, 2021 37 Exhibit C - Law 360 Article (4)
Jul 28, 2021 37 Exhibit D - July Email (2)
Jul 28, 2021 37 Exhibit E - Production Letter (3)
Jul 28, 2021 37 Exhibit F - Correspondence (6)
Jul 28, 2021 37 Exhibit G - 11-2-2006 Order (4)
Jul 28, 2021 37 Exhibit H - Opinion (9)
Jul 28, 2021 38 Declaration (8)
Docket Text: DECLARATION of Stephen Cary in Opposition to [36] Opposition/Response to Motion filed byHanda Neuroscience, LLC. (Related document(s)[36]) (Mizerk, Donald) (Filed on 7/28/2021) [Transferred from California Northern on 3/21/2022.]
Jul 27, 2021 N/A Notice (Other) (0)
Docket Text: CLERK'S NOTICE CONTINUING HEARING. Please take NOTICE that the Initial Case Management Conference set for 8/5/2021 is HEREBY CONTINUED to 9/30/2021 10:00 AM in San Jose, Courtroom 4, 5th Floor. Updated Joint Case Management Statement due by 9/20/2021. (This is a text-only entry generated by the court. There is no document associated with this entry.) (amkS, COURT STAFF) (Filed on 7/27/2021) [Transferred from California Northern on 3/21/2022.]
Jul 26, 2021 34 Statement (27)
Docket Text: CASE MANAGEMENT STATEMENT (Joint) filed by Novartis Pharmaceuticals Corporation. (Love, Jane) (Filed on 7/26/2021) [Transferred from California Northern on 3/21/2022.]
Jul 20, 2021 32 Notice of Appearance (2)
Docket Text: NOTICE of Appearance by Anne Yen-Chen Brody for Novartis Pharmaceuticals Corporation (Brody, Anne) (Filed on 7/20/2021) [Transferred from California Northern on 3/21/2022.]
Jul 20, 2021 33 Answering Brief in Opposition (26)
Docket Text: OPPOSITION/RESPONSE (re [24] MOTION for Judgment on the Pleadings ) filed byNovartis Pharmaceuticals Corporation. (Love, Jane) (Filed on 7/20/2021) [Transferred from California Northern on 3/21/2022.]
Jul 15, 2021 31 Notice (Other) (1)
Docket Text: ADR Certification (ADR L.R. 3-5 b) of discussion of ADR options (Hsin, Yu-Chieh) (Filed on 7/15/2021) [Transferred from California Northern on 3/21/2022.]
Jun 30, 2021 30 Order on Motion to Stay (5)
Docket Text: Order Granting [29] Stipulation Extending Briefing Schedule for Plaintiff's Motion to Stay. Signed by Judge Edward J. Davila on 06/30/2021. (ejdlc2S, COURT STAFF) (Filed on 6/30/2021) [Transferred from California Northern on 3/21/2022.]
Jun 29, 2021 29 Stipulation (5)
Docket Text: STIPULATION WITH PROPOSED ORDER re [28] MOTION to Stay in Favor of First-Filed Case (Extending Briefing Schedule) filed by Novartis Pharmaceuticals Corporation. (Hsin, Yu-Chieh) (Filed on 6/29/2021)[Transferred from California Northern on 3/21/2022.]
Jun 22, 2021 27 Order on Motion to Stay (4)
Docket Text: Order Granting [26] Stipulation Extending Briefing Schedule for Motion for Judgment on the Pleadings. Signed by Judge Edward J. Davila on 06/22/2021. (ejdlc2S, COURT STAFF) (Filed on 6/22/2021) [Transferred from California Northern on 3/21/2022.]
Jun 22, 2021 28 Main Document (18)
Docket Text: MOTION to Stay in Favor of First-Filed Case filed by Novartis Pharmaceuticals Corporation. Motion Hearing set for 9/9/2021 09:00 AM in San Jose, Courtroom 4, 5th Floor before Judge Edward J. Davila. Responses due by 7/6/2021. Replies due by 7/13/2021. (Attachments: # (1) Declaration of R. Trenchard, # (2) Exhibit 1, Trenchard Decl., # (3) Exhibit 2, Trenchard Decl., # (4) Exhibit 3, Trenchard Decl., # (5) Exhibit 4, Trenchard Decl., # (6) Exhibit 5, Trenchard Decl., # (7) Exhibit 6, Trenchard Decl., # (8) Exhibit 7, Trenchard Decl., # (9) Exhibit 8, Trenchard Decl., # (10) Proposed Order)(Hsin, Yu-Chieh) (Filed on 6/22/2021) [Transferred from California Northern on 3/21/2022.]
Jun 22, 2021 28 Declaration of R. Trenchard (3)
Jun 22, 2021 28 Exhibit 1, Trenchard Decl. (26)
Jun 22, 2021 28 Exhibit 2, Trenchard Decl. (45)
Jun 22, 2021 28 Exhibit 3, Trenchard Decl. (103)
Jun 22, 2021 28 Exhibit 4, Trenchard Decl. (14)
Jun 22, 2021 28 Exhibit 5, Trenchard Decl. (10)
Jun 22, 2021 28 Exhibit 6, Trenchard Decl. (18)
Jun 22, 2021 28 Exhibit 7, Trenchard Decl. (4)
Jun 22, 2021 28 Exhibit 8, Trenchard Decl. (3)
Jun 22, 2021 28 Proposed Order (2)
Jun 21, 2021 26 Stipulation (4)
Docket Text: STIPULATION WITH PROPOSED ORDER re [24] MOTION for Judgment on the Pleadings (Extending Briefing Schedule) filed by Novartis Pharmaceuticals Corporation. (Hsin, Yu-Chieh) (Filed on 6/21/2021)[Transferred from California Northern on 3/21/2022.]
Jun 15, 2021 23 Answer to Complaint (27)
Docket Text: ANSWER to Complaint byHanda Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc., Handa Pharmaceuticals, LLC. (Mizerk, Donald) (Filed on 6/15/2021) [Transferred from California Northern on 3/21/2022.]
Jun 15, 2021 24 Motion for Judgment on the Pleadings (27)
Docket Text: MOTION for Judgment on the Pleadings filed by Handa Neuroscience, LLC. Motion Hearing set for 9/9/2021 09:00 AM in San Jose, Courtroom 4, 5th Floor before Judge Edward J. Davila. Responses due by 6/29/2021. Replies due by 7/6/2021. (Mizerk, Donald) (Filed on 6/15/2021) [Transferred from California Northern on 3/21/2022.] Modified on 4/29/2022 (dlw).
Jun 15, 2021 25 Main Document (3)
Docket Text: Declaration of Don J. Mizert in Support of [24] MOTION for Judgment on the Pleadings filed byHanda Neuroscience, LLC. (Attachments: # (1) Exhibit 1 - '179 Pros. History, # (2) Exhibit 2 - Garber, # (3) Exhibit 3 - Tyler, # (4) Exhibit 4 - Arvin, # (5) Exhibit 5 - VARIVAX Label, # (6) Exhibit 6 - Physicians' Desk Ref., # (7) Exhibit 7 - ZOSTAVAX Label, # (8) Exhibit WO2008000419A1, # (9) Exhibit Schmouder)(Related document(s)[24]) (Mizerk, Donald) (Filed on 6/15/2021) [Transferred from California Northern on 3/21/2022.]
Jun 15, 2021 25 Exhibit 1 - '179 Pros. History (379)
Jun 15, 2021 25 Exhibit 2 - Garber (3)
Jun 15, 2021 25 Exhibit 3 - Tyler (5)
Jun 15, 2021 25 Exhibit 4 - Arvin (21)
Jun 15, 2021 25 Exhibit 5 - VARIVAX Label (16)
Jun 15, 2021 25 Exhibit 6 - Physicians' Desk Ref. (7)
Jun 15, 2021 25 Exhibit 7 - ZOSTAVAX Label (24)
Jun 15, 2021 25 Exhibit WO2008000419A1 (23)
Jun 15, 2021 25 Exhibit Schmouder (3)
Jun 14, 2021 21 Notice of Appearance (3)
Docket Text: NOTICE of Appearance by Donald J Mizerk (Mizerk, Donald) (Filed on 6/14/2021) [Transferred from California Northern on 3/21/2022.]
Jun 14, 2021 22 Disclosure Statement (2)
Docket Text: Certificate of Interested Entities by Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc., Handa Pharmaceuticals, LLC identifying Corporate Parent Handa Pharmaceuticals, Inc. for Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, LLC. (Mizerk, Donald) (Filed on 6/14/2021) [Transferred from California Northern on 3/21/2022.]
May 21, 2021 20 Order on Motion to Stay (5)
Docket Text: Order Granting [19] Stipulation Governing Acceptance of Service of Process and Response Time to Complaint. Signed by Judge Edward J. Davila on 05/21/2021. (ejdlc2S, COURT STAFF) (Filed on 5/21/2021)[Transferred from California Northern on 3/21/2022.]
May 20, 2021 19 Stipulation (5)
Docket Text: STIPULATION WITH PROPOSED ORDER Governing Acceptance of Service of Process and Response Time to Complaint filed by Novartis Pharmaceuticals Corporation. (Hsin, Yu-Chieh) (Filed on 5/20/2021) [Transferred from California Northern on 3/21/2022.]
May 18, 2021 17 Main Document (1)
Docket Text:ORDER REASSIGNING CASE. Case reassigned using a proportionate, random, and blind system pursuant to General Order No. 44 to Judge Edward J. Davila for all further proceedings. Magistrate Judge Laurel Beeler no longer assigned to case, Notice: The assigned judge participates in the Cameras in the Courtroom Pilot Project. See General Order No. 65 and http://cand.uscourts.gov/cameras.. Signed by Clerk on 05/18/2021. (Attachments: # (1) Notice of Eligibility for Video Recording)(mbcS, COURT STAFF) (Filed on 5/18/2021) [Transferred from California Northern on 3/21/2022.]
May 18, 2021 17 Notice of Eligibility for Video Recording (1)
May 18, 2021 N/A Notice (Other) (0)
Docket Text: (Text Only) CLERKS NOTICE RESETTING CASE MANAGEMENT CONFERENCE FOLLOWING REASSIGNMENT. Joint Case Management Statement due by 7/26/2021. Initial Case Management Conference set for 8/5/2021 10:00 AM in San Jose, Courtroom 4, 5th Floor before Hon. Edward J. Davila. The Court does not issue a revised Initial Case Management Scheduling Order with ADR Deadlines. Standing orders can be downloaded from the court's web page at http://cand.uscourts.gov/ejdorders. This is a text only docket entry, there is no document associated with this notice. (amkS, COURT STAFF) (Filed on 5/18/2021) [Transferred from California Northern on 3/21/2022.]
May 17, 2021 15 Magistrate Consent Forms (1)
Docket Text: CONSENT/DECLINATION to Proceed Before a US Magistrate Judge by Novartis Pharmaceuticals Corporation.. (Love, Jane) (Filed on 5/17/2021) [Transferred from California Northern on 3/21/2022.]
May 17, 2021 N/A Remark (0)
Docket Text: CLERK'S NOTICE OF IMPENDING REASSIGNMENT TO A U.S. DISTRICT COURT JUDGE: The Clerk of this Court will now randomly reassign this case to a District Judge because either (1) a party has not consented to the jurisdiction of a Magistrate Judge, or (2) time is of the essence in deciding a pending judicial action for which the necessary consents to Magistrate Judge jurisdiction have not been secured. You will be informed by separate notice of the district judge to whom this case is reassigned.

ALL HEARING DATES PRESENTLY SCHEDULED BEFORE THE CURRENT MAGISTRATE JUDGE ARE VACATED AND SHOULD BE RE-NOTICED FOR HEARING BEFORE THE JUDGE TO WHOM THIS CASE IS REASSIGNED.

This is a text only docket entry; there is no document associated with this notice. (ejkS, COURT STAFF) (Filed on 5/17/2021) [Transferred from California Northern on 3/21/2022.]

May 13, 2021 11 Main Document (1)
Docket Text: MOTION for leave to appear in Pro Hac Vice for Novartis Pharmaceuticals Corporation ( Filing fee $ 317, receipt number 0971-15961378.) filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certificate of Good Standing)(Love, Jane) (Filed on 5/13/2021) [Transferred from California Northern on 3/21/2022.]
May 13, 2021 11 Certificate of Good Standing (2)
May 13, 2021 12 Main Document (1)
Docket Text: MOTION for leave to appear in Pro Hac Vice for Novartis Pharmaceuticals Corporation ( Filing fee $ 317, receipt number 0971-15962038.) filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certificate of Good Standing)(Trenchard, Robert) (Filed on 5/13/2021) [Transferred from California Northern on 3/21/2022.]
May 13, 2021 12 Certificate of Good Standing (2)
May 13, 2021 13 SO ORDERED (3)
Docket Text:Order by Magistrate Judge Laurel Beeler granting [11] Motion for Pro Hac Vice. Attorney Jane M Love representing Plaintiff. (ejkS, COURT STAFF) (Filed on 5/13/2021) [Transferred from California Northern on 3/21/2022.]
May 13, 2021 14 SO ORDERED (3)
Docket Text:Order by Magistrate Judge Laurel Beeler granting [12] Motion for Pro Hac Vice. Attorney Robert W Trenchard representing Plaintiff. (ejkS, COURT STAFF) (Filed on 5/13/2021) [Transferred from California Northern on 3/21/2022.]
May 11, 2021 9 Order (2)
Docket Text:Initial Case Management Scheduling Order with ADR Deadlines: Case Management Statement due by 7/29/2021. Initial Case Management Conference set for 8/5/2021 11:00 AM in San Francisco, Courtroom B, 15th Floor. (gbaS, COURT STAFF) (Filed on 5/11/2021) [Transferred from California Northern on 3/21/2022.]
May 11, 2021 10 Summons Issued (8)
Docket Text: Summons Issued as to Handa Neuroscience, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc., Handa Pharmaceuticals, LLC. (gbaS, COURT STAFF) (Filed on 5/11/2021) [Transferred from California Northern on 3/21/2022.]
May 6, 2021 1 *Restricted* (0)
Docket Text:**Erroneous Entry - please disregard and refer to Docket No. [7]**

COMPLAINT for Patent Infringement against All Defendants (Filing fee $ 402, receipt number 0971-15936857.). Filed byNovartis Pharmaceuticals Corporation. (Attachments: # (1) Civil Cover Sheet)(Hsin, Yu-Chieh) (Filed on 5/6/2021) Modified on 5/10/2021 (gbaS, COURT STAFF). [Transferred from California Northern on 3/21/2022.]
May 6, 2021 1 Civil Cover Sheet (2)
May 6, 2021 2 Main Document (2)
Docket Text: Proposed Summons. (Attachments: # (1) Summons (Handa Pharmaceuticals Inc), # (2) Summons (Handa Pharma Inc), # (3) Summons (Handa Pharmaceuticals LLC))(Hsin, Yu-Chieh) (Filed on 5/6/2021) [Transferred from California Northern on 3/21/2022.]
May 6, 2021 2 Summons (Handa Pharmaceuticals Inc) (2)
May 6, 2021 2 Summons (Handa Pharma Inc) (2)
May 6, 2021 2 Summons (Handa Pharmaceuticals LLC) (2)
May 6, 2021 3 Patent/Trademark Report to Commissioner (1)
Docket Text: REPORT on the filing of an action regarding Patent Nos. 9,187,405 and 10,543,179 (cc: form mailed to register). (Hsin, Yu-Chieh) (Filed on 5/6/2021) Modified on 5/11/2021 (gbaS, COURT STAFF). [Transferred from California Northern on 3/21/2022.]
May 6, 2021 4 Disclosure Statement (2)
Docket Text: Certificate of Interested Entities by Novartis Pharmaceuticals Corporation identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation. (Hsin, Yu-Chieh) (Filed on 5/6/2021)[Transferred from California Northern on 3/21/2022.]
May 6, 2021 5 Notice (Other) (3)
Docket Text: NOTICE of Pendency of Other Action Involving Same Patent by Novartis Pharmaceuticals Corporation (Hsin, Yu-Chieh) (Filed on 5/6/2021) [Transferred from California Northern on 3/21/2022.]
May 6, 2021 6 Patent/Trademark Report to Commissioner (2)
Docket Text: NOTICE of Errata by Novartis Pharmaceuticals Corporation re [1] Complaint (Hsin, Yu-Chieh) (Filed on 5/6/2021) Modified on 5/11/2021 (gbaS, COURT STAFF). [Transferred from California Northern on 3/21/2022.]
May 6, 2021 7 Main Document (20)
Docket Text: CORRECTED COMPLAINT for Patent Infringement (replacing document [1] ) against All Defendants. Filed byNovartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, Complaint, # (2) Exhibit B, Complaint, # (3) Exhibit C, Complaint, # (4) Civil Cover Sheet)(Hsin, Yu-Chieh) (Filed on 5/6/2021) Modified on 5/10/2021 (gbaS, COURT STAFF). [Transferred from California Northern on 3/21/2022.]
May 6, 2021 7 Exhibit A, Complaint (12)
May 6, 2021 7 Exhibit B, Complaint (17)
May 6, 2021 7 Exhibit C, Complaint (33)
May 6, 2021 7 Civil Cover Sheet (2)
Menu